Literature DB >> 30121394

Surgery in Malignant Pleural Mesothelioma.

Raphael Bueno1, Isabelle Opitz2.   

Abstract

Surgical intervention plays an important role in the diagnosis, staging, and treatment of malignant pleural mesothelioma (MPM) and can be applied with curative or palliative intent. The overall aim of surgery should be, as in any oncologic surgery, the macroscopic complete resection (MCR) of the tumor. Most importantly, the majority of patients with the diagnosis of MPM should be appropriately staged and initially evaluated in a multidisciplinary setting, including medical oncology, radiation oncology, and surgery after histologic diagnosis. Surgical staging, including determination of the histologic subtype and lymph node status, as well as clinical staging with positron-emission tomography-computer tomography scan and determination of cardiopulmonary reserve are crucial. Herein, we summarize the role of surgical resection, specifically macroscopic complete resection, performed as extrapleural pneumonectomy or extended pleurectomy/decortication in multimodality treatment settings and advocate for optimal patient selection for one or the other procedure. In addition, the roles of surgery in diagnosis of MPM and in palliative care are discussed.
Copyright © 2018 International Association for the Study of Lung Cancer. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30121394     DOI: 10.1016/j.jtho.2018.08.001

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  13 in total

Review 1.  New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options.

Authors:  Anne S Tsao; Harvey I Pass; Andreas Rimner; Aaron S Mansfield
Journal:  J Clin Oncol       Date:  2022-01-05       Impact factor: 44.544

2.  Mitogen signal-associated pathways, energy metabolism regulation, and mediation of tumor immunogenicity play essential roles in the cellular response of malignant pleural mesotheliomas to platinum-based treatment: a retrospective study.

Authors:  Alexander Mathilakathu; Sabrina Borchert; Michael Wessolly; Elena Mairinger; Hendrik Beckert; Julia Steinborn; Thomas Hager; Daniel C Christoph; Jens Kollmeier; Jeremias Wohlschlaeger; Thomas Mairinger; Kurt Werner Schmid; Robert F H Walter; Luka Brcic; Fabian D Mairinger
Journal:  Transl Lung Cancer Res       Date:  2021-07

3.  Routine surveillance for diagnosis of venous thromboembolism after pleurectomy for malignant pleural mesothelioma.

Authors:  Luis E De León; Carlos E Bravo-Iñiguez; Sam Fox; Jeffrey Tarascio; Samuel Freyaldenhoven; Moshe Lapidot; Michael T Jaklitsch; Raphael Bueno
Journal:  J Thorac Cardiovasc Surg       Date:  2020-01-30       Impact factor: 5.209

4.  Quantitation and predictors of short-term mortality following extrapleural pneumonectomy, pleurectomy/decortication, and nonoperative management for malignant pleural mesothelioma.

Authors:  Christopher Wright; Vivek Verma; Andrew R Barsky; Waqar Haque; Praveen V Polamraju; Ethan B Ludmir; Nicholas G Zaorsky; Eric J Lehrer; Daniel M Trifiletti; Surbhi Grover; Joseph S Friedberg; Charles B Simone
Journal:  J Thorac Dis       Date:  2020-11       Impact factor: 2.895

5.  Metastasis-associated gene 1 (MTA1) enhances cisplatin resistance of malignant pleural mesothelioma by ATR-Chk1-mediated DNA repair.

Authors:  Caihua Xu; Yufeng Hu; Bin Chen; Dapeng Li; Rongrui Liang; Meng Shen; Mengyao Wu; Min Tao
Journal:  Ann Transl Med       Date:  2021-04

6.  Ki67 (MIB-1) as a Prognostic Marker for Clinical Decision Making Before Extended Pleurectomy Decortication in Malignant Pleural Mesothelioma.

Authors:  Robert A Belderbos; Alexander P W M Maat; Sara J Baart; Eva V E Madsen; Ad J J C Bogers; Robin Cornelissen; Joachim G J V Aerts; Edris A F Mahtab; Jan H von der Thüsen
Journal:  JTO Clin Res Rep       Date:  2021-02-15

7.  Evidence for marked underutilization of insurance billing in malignant pleural mesothelioma in Finland.

Authors:  Paulus Torkki; Juuso Paajanen; Ville Kytö; Sanna Laaksonen; Jari Räsänen; Marjukka Myllärniemi; Ilkka Ilonen
Journal:  Thorac Cancer       Date:  2021-09-13       Impact factor: 3.500

8.  UHRF1 Is a Novel Druggable Epigenetic Target in Malignant Pleural Mesothelioma.

Authors:  Emily S Reardon; Vivek Shukla; Sichuan Xi; Sudheer K Gara; Yi Liu; David Straughan; Mary Zhang; Julie A Hong; Eden C Payabyab; Anju Kumari; William G Richards; Assunta De Rienzo; Raffit Hassan; Markku Miettinen; Liqiang Xi; Mark Raffeld; Lisa T Uechi; Xinmin Li; Ruihong Wang; Haobin Chen; Chuong D Hoang; Raphael Bueno; David S Schrump
Journal:  J Thorac Oncol       Date:  2020-09-11       Impact factor: 15.609

9.  Extended pleurectomy and decortication: Video atlas of operative steps.

Authors:  R Taylor Ripley; Nihanth Palivela
Journal:  JTCVS Tech       Date:  2021-03-24

10.  Sarcopenia, Precardial Adipose Tissue and High Tumor Volume as Outcome Predictors in Surgically Treated Pleural Mesothelioma.

Authors:  Oliver Guido Verhoek; Lisa Jungblut; Olivia Lauk; Christian Blüthgen; Isabelle Opitz; Thomas Frauenfelder; Katharina Martini
Journal:  Diagnostics (Basel)       Date:  2022-01-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.